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Abstract 
 
 This study evaluated the use of heat-stable enterotoxin (ST), a guanylate cyclase 
receptor type C (GC-C) agonist, in combination with celecoxib, a cyclooxygenase-2 
(COX-2) inhibitor, for the prevention of colorectal cancer (CRC) growth in vitro. GC-C 
is a membrane-bound enzyme found in the lumen of the intestines and is responsible for 
the conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate 
(cGMP). Activation of GC-C elevates intracellular cGMP which controls fluid-ion 
homeostasis and enterocyte differentiation along the crypt-villus axis.  GC-C function can 
regulate colonic cell proliferation and induce cell cycle arrest. COX-2 is a cytosolic 
enzyme that catalyzes the formation of prostaglandins from arachidonic acid and 
inhibition of this enzyme is known to inhibit proliferation of human cancer cells. 
Previous research demonstrated that inhibition of the primary enzyme responsible for 
degradation of cGMP potentiated the cytostatic effects of celecoxib. This thesis tested if 
GC-C activation can enhance the antiproliferative effects of celecoxib.  
 Cell proliferation was assessed using a thymidine incorporation protocol, in which 
cells are cultured with tritiated thymidine after treatment and the amount of measured 
incorporated radioactivity correlates with cell division. Celecoxib was found to inhibit 
proliferation of T84 cells, which are derived from a human colorectal adenocarcinoma. 
This was consistent with previous studies that demonstrated an anti-proliferative effect of 
celecoxib in other human cancer cell lines. However, the addition of ST to celecoxib was 
    
 
unable to potentiate the anti-proliferative effects of celecoxib. ST also had no effect on 
proliferation when used as a monotherapy.  
 Changes in COX-2 activity, as well as the presence of COX-2 enzyme, were 
measured to assess whether the effect of celecoxib in T84 cells was dependent on its 
inhibitory activity on COX-2. No changes in cyclooxygenase activity were observed and 
COX-2 was not detected in T84 cells. In addition, celecoxib and the combination of 
celecoxib and ST were unable to produce a detectable amount of Caspase-3, a marker of 
cell death, suggesting that these drugs do not have a cytotoxic effect in T84 cells. 
 This research showed that ST does not have an effect on proliferation of T84 
cells, which conflicts with previous research conducted by Pitari et al. (2001). It is 
possible that an effect of ST on adenocarcinomas in the gastrointestinal tract may vary 
based on the location of the targeted cells. Therefore, while ST did not reduce 
proliferation on cells derived from the colon, it may have an effect on proliferation of 
epithelial cells that are located in the small intestine upstream from the colon. Celecoxib 
was confirmed to have an anti-proliferative effect, and this was shown to be independent 
of the drugs enzymatic target, implying that there are additional mechanisms through 
which celecoxib exerts its activity. Additional research is needed to clarify these 
mechanisms.
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Chapter I 
Introduction 
 
Colorectal Cancer 
 Colorectal cancer (CRC) is the third most common form of cancer worldwide, 
after lung and breast cancer (Singh, Montalban, & Mahmud, 2014). Accounting for 
approximately 600,000 deaths worldwide in 2008, CRC is also the fourth most common 
cause of cancer deaths, after lung, stomach, and liver cancer, and is the second most 
common cause of cancer death in developed countries. While CRC incidence and 
mortality rates have been declining in most developed countries over the past two 
decades (Yau et al. 2008), rates have actually been climbing in developing countries. 
With growing elderly populations across the world, even developed countries are likely 
to see an increase in the total number of patients diagnosed with CRC. 
Nearly all colorectal cancers are adenocarcinomas (Bardhan & Liu, 2013). Most 
colorectal cancers begin with the development of polyps on the epithelial lining of the 
large bowel. Polyps may initially be benign growths, commonly referred to as 
hyperplastic polyps. Pre-malignant polyps, or adenomas, are the next step in progression 
to CRC. CRC typically develops slowly, over the course of many years. During this time, 
polyps or adenomas can progress to a malignant state, at which point they are termed 
adenocarcinomas.  
While about 20% of CRC patients have a family history of CRC, the majority of 
cases are linked to environmental factors, particularly diet and lifestyle. Researchers have 
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recently identified additional CRC risk factors including the composition of the intestinal 
microbiome and the presence of intestinal inflammation (Zhu, Gao, Wu, & Qin, 2013). 
Aberrant cellular activities at a variety of levels can eventually lead to progression of 
luminal intestinal tissue from normal glandular epithelium to adenocarcinomas 
(Markowitz & Bertagnolli, 2009). At the chromosomal level, CRC is associated with 
many rare inactivating mutations of genes that normally maintain chromosomal stability. 
In some patients, genes required for DNA repair (mismatch-repair genes) are inactivated. 
This inactivation can be inherited, or may result from epigenetic silencing as a 
consequence changes in DNA methylation. Epigenetic silencing can similarly result in a 
lack of chromosome-stabilizing genes.  
The importance of epigenetic factors in CRC development has become 
increasingly understood over the last several decades (Bardhan & Liu, 2013). While the 
term epigenetics can be used to describe several non-coded mechanisms for altering DNA 
expression, changes in chromatin conformation appear to be particularly relevant in 
cancers in general and CRC in particular.  By altering the extent to which DNA is 
accessible to transcription factors, epigenetic variations can lead to differences in 
activation or repression of transcription. In the CRC setting, it appears that variations in 
DNA methylation and modifications to histones proximal to gene promoters are the 
predominant epigenetic factors contributing to CRC development.  
Chromosomal instability, DNA-repair defects, or altered DNA methylation can 
dramatically accelerate the accumulation of DNA mutations that can eventually lead to 
the development of CRC. Mutations in the Wnt pathway are particularly common in CRC 
tissue (Bardhan & Liu, 2013). Specifically, mutations in the adenomatous polyposis coli 
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gene (APC), which are observed in 85% of CRC (Markowitz & Bertagnolli, 2010), lead 
to activation of the Wnt pathway and polyp formation. Subsequent mutations to the 
proto-oncogenes KRAS or BRAF (via MAPK activation) or to TP53, β-Catenin, SMAD4, 
TGFβ receptor II (TGFBR2), or several other genes appear to facilitate progression from 
polyp to cancer by inducing proliferation and suppressing apoptosis. While these appear 
to be the most common etiologies in CRC pathogenesis, the molecular basis of the 
disease is not entirely understood, and numerous less prevalent mutations are also 
implicated in the pathogenic process (Bardhan & Liu, 2013).  
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Adapted from (Markowitz & Bertagnolli, 2009). 
Figure 1. Factors Contributing to Progression of CRC.
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Once a polyp develops into an advanced adenoma or early carcinoma, various 
growth and stem-cell factors can contribute to growth and metastasis of the cancer 
(Markowitz & Bertagnolli, 2010). An early step in adenoma growth is activation of 
prostaglandin signaling and growth factor signaling, which can occur in response to 
inflammation or increased expression of cyclooxygenase 2 (COX-2). Epidermal growth 
factor (EGF), which acts through the EFG receptor (EGFR) and the MAPK pathway, 
causes trophic effects that can promote metastasis. The angiogenesis-inducing vascular 
endothelial growth factor (VEGF) also promotes growth and spreading of tumors that are 
early in their development. 
Certain individuals are heavily predisposed to polyp development and subsequent 
adenocarcinoma due to an inherited disease caused by specific genetic factors. One such 
disease is familial adenomatous polyposis (FAP). FAP is caused by mutations in the APC 
tumor suppressor gene which lead to constitutive β-catenin activity and subsequent 
hyper-proliferation (Plawski et al., 2013).  As a result of this proliferation, individuals 
with FAP can develop hundreds of polyps, which typically begin to appear around age 
15. With such an overabundance of polyps, these patients are at considerably higher risk 
of developing CRC. Individuals with mutations in the MUTYH gene may present with a 
similar phenotype; this autosomal recessive disease is referred to as MUTYH 
adenomatous polyposis (MAP).  
Lynch Syndrome, or hereditary nonpolyposis colorectal cancer (HNPCC), is the 
most common form of inherited susceptibility to CRC (Sehgal, Sheahan, O’Connell, 
Hanly, Martin, & Winter, 2014). Unlike FAP or MAP, however, HNPCC describes a 
collection of mutations to DNA mismatch repair syndromes. Also unlike the polyposis 
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described above, HNPCC does not necessarily lead to a massive number of polyps. The 
risk of CRC in individuals with HNPCC results mainly from the enhanced risk of 
progression from an adenoma to a carcinoma in patients with the disease. In fact, 
virtually every adenoma in HNPCC patients will progress to a carcinoma. In individuals 
without HNPCC, only approximately 1 in 30 adenomas will become a carcinoma.  
 
Treatment and Prevention of CRC  
 Localized or advanced colorectal carcinomas require surgical removal of the 
tumor (Courtney, McDermott, Heeney, & Winter, 2014). Surgical or endoscopic 
interventions substantially reduce recurrence and increase 5-year survival rates and are 
the mainstay of treatment in all CRC patients, with the exception of those with metastatic 
disease (Ahmed, Johnson, Ahmed, & Iqbal, 2014).  
Postoperative chemotherapy is generally indicated in patients with advanced 
disease in which the cancer has been detected in neighboring lymph nodes (Tol & Punt, 
2010). In these patients, chemotherapy reduces the likelihood of CRC recurrence and 
increases cure rates. However, adjuvant chemotherapy in patients whose cancer has not 
yet spread to lymph nodes is controversial. Adjuvant chemotherapy regimens have 
historically used the thymidylate synthase (TS) inhibitor 5-fluorouracil (5-FU) as the base 
of treatment. Levamisole, leucovorin, capecitabine, oxaliplatin, and numerous other 
compounds have since been added to the CRC treatment algorithm. Recent approvals of 
biological therapies including the anti-VEGF antibody, bevacizumab, and the anti-EGFR 
antibodies, cetuximab and panitumumab, have given physicians additional options for 
7 
 
treating advanced and metastatic CRC. Recent evidence also suggests that changes in 
lifestyle factors, such as diet and exercise, can improve the prognosis in CRC patients 
after resection of their tumor(s) (Meyerhardt et al., 2013). 
 In spite of the recently expanded arsenal of CRC treatments, 5-year survival in 
patients with distant metastases is less than 10% (Ahmed, Johnson, Ahmed, & Iqbal, 
2014). As is the case when managing many other cancers, early detection and prevention 
of malignant growth and subsequent metastases are the primary goals of CRC treatment. 
The development and approval of new chemotherapeutic agents that prevent tumor 
growth and metastasis could substantially improve outcomes for patients with CRC.  In 
certain patient populations, such as those with early polyps, significant genetic 
predisposition towards CRC, or those with FAP, early chemoprevention of further polyp 
growth with drugs such as aspirin may delay the development of a carcinoma.  
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Adapted from (Ahmed, Johnson, Ahmed, & Iqbal, 2014). 
Figure 2. Framework for Managing Colorectal Cancer.  
In patients with FAP or HNPCC, aspirin has not been found to produce a 
statistically significant reduction in polyp number, although it may reduce the size of 
polyps. On the other hand, a meta-analysis of four studies in individuals with previous 
history of adenomas or CRC found that aspirin did, in fact, provide a statistically 
significant 21% reduction in the relative risk (RR) of developing a recurrent adenoma(s). 
Furthermore, high dose aspirin treatment was found to reduce CRC incidence by a 
statistically significant 26% over a 23-year follow-up period. Interestingly, this effect was 
not detected over the first 10 years (Cooper et al., 2010).  
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 Certain nonsteroidal anti-inflammatory drugs (NSAIDs) other than aspirin, such 
as sulindac, celecoxib, and tiracoxib, have also been evaluated in their ability to prevent 
adenoma or CRC incidence (Cooper et al., 2010). The studies evaluating these drugs in 
FAP patients have been very small. Nevertheless, five studies found that they were able 
to reduce polyp number and size. Celecoxib has also been evaluated in patients with 
history of adenomas over a 3-year follow-up period. Prevention with celecoxib was 
associated with a statistically significant 34% reduction in the RR of adenoma recurrence 
and a 55% reduction in the RR of incidence of advanced adenomas.  
There appears to be a beneficial effect of chronic use of aspirin and other NSAIDs 
in reducing adenoma and CRC incidence (Cooper et al., 2010). Such use may be limited, 
however, due to concerns about the safety profiles of these types of drugs. For instance, 
aspirin is associated with gastrointestinal bleeding and other GI toxicities and some 
inhibitors of cyclooxygenase-2 have been associated with increased risk of serious 
cardiovascular events. This topic is discussed in more depth below. Because of these less-
than-ideal safety profiles, it is worthwhile to investigate the use of other drugs that may 
be used in combination with NSAIDs to prevent CRC.  The desired preventative effect 
would ideally be achieved using sub-toxic doses of both drugs. One potential approach 
for slowing CRC progression that has been described by certain academic groups is 
activation of the enzyme Guanylate Cyclase C, which has been shown to suppress 
intestinal inflammation and colon cell proliferation.  
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Guanylate Cyclase-C (GC-C) 
 Guanylate, or guanylyl, cyclases are a highly conserved family of enzymes that 
catalyze the conversion of cytosolic guanosine triphosphate (GTP) to the second 
messenger cyclic guanosine-3’,5’- monophosphate (cGMP) in response to a variety of 
signals, depending on the specific guanylate cyclase (Lucas et al., 2000). cGMP was first 
identified in 1963 and the enzymes that catalyze its formation from GTP (i.e. the 
guanylate cyclases) were discovered 6 years later (Potter, 2011).  cGMP modulates a 
variety of many physiological activities including neurotransmission, blood pressure, 
platelet aggregation, and fluid secretion. In the decades since cGMP and the first 
guanylate cyclase were discovered, eleven total guanylate cyclases, including four 
soluble proteins and seven membrane-spanning forms, have been found to be expressed 
in mammals.  
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Image adapted from (Lucas et al., 2000) 
Figure 3. Catalytic Mechanism of Guanylate Cyclase Activity.  
GC-C converts linear GTP to cyclic GMP. 
 
Guanylate cyclase C (GC-C) is expressed primarily in the intestinal epithelium, 
and is found in the apical membrane of gut epithelial cells (Potter, 2011). The 
extracellular ligand binding domain is coupled to the intracellular carboxyl terminal 
guanylate cyclase domain by a transmembrane region and an intracellular kinase 
homology domain. The catalytic domain is homologous to that of adenylyl cyclase, and is 
highly conserved across the guanylate cyclase family (Lucas et al., 2000).  
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The endogenous paracrine peptide hormones, guanylin and uroguanylin, as well 
as the heat-stable enterotoxin (ST), which is produced by various intestine-colonizing 
bacteria, bind to and activate GC-C, causing an increase in intracellular cGMP, which 
plays several roles in regulating cellular physiology (Arshad & Visweswariah, 2012). 
While guanylin and uroguanylin both bind GC-C in the lumen of the gastrointestinal 
tract, the two peptides differ in terms of their structure, stability and therefore, their 
cGMP-stimulating potency in different parts of the gut. Whereas uroguanylin is 
approximately 100-fold more potent than guanylin at pH 5.0, the relative potencies are 
reversed at an alkaline pH of 8.0 (Nakazato, 2001).  
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Adapted from (Taxt, Aasland, Sommerfelt, Nataro, & Puntervoll, 2010). 
Figure 4. Structure and Primary Sequences of GC-C Agonists. 
(A). Structures of human uroguanylin and the active domain of ST. (B). Amino acid 
sequences of various GC-C agonists.  
 
In response to GC-C activation by guanylin, uroguanylin, ST, or other GC-C 
agonists, cGMP accumulates and activates cGMP-dependent protein kinase II (PKG II), 
which phosphorylates the cystic fibrosis transmembrane conductance regulator (CFTR) 
chloride channel (Arshad & Visweswariah, 2012). cGMP also inhibits the activity of 
PDE3, a cAMP-specific phosphodiesterase, resulting in activation of PKA. PKA 
phosphorylates the CFTR channel as well. CFTR phosphorylation results in a 
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continuously open structure, which allows chloride ions to flow out of the cell into the 
intestinal lumen. PKGII also leads to the efflux of bicarbonate ions and causes the 
inhibition of the sodium-hydrogen exchanger, NHE3 (Arshad & Visweswariah, 2012). 
These activities, coupled with CFTR phosphorylation, lead to a net reduction in sodium 
ion absorption and net fluid secretion into the intestinal lumen.  
 
 
Adapted from (Arshad & Visweswariah, 2012).  
Figure 5.  Summary of GC-C Signaling. 
Activation of GC-C leads to an increase in intracellular cGMP, which ultimately leads to 
chloride and bicarbonate secretion in the intestinal lumen, which causes net fluid 
secretion into the gut.  
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Linaclotide, a peptide with 14 amino acids contains 3 disulfide bonds, is a potent 
GC-C agonist approved in the United States and several other countries for constipation-
predominant irritable bowel syndrome (IBS-C) and chronic idiopathic constipation (CIC) 
(Busby et al., 2012).  Linaclotide has been shown to improve both motility and pain 
symptoms in patients (Quigley et al., 2013).  Multiple other GC-C peptide agonists, 
including IW-9179, plecanatide, and dolcanatide (the latter two are uroguanylin analogs), 
are currently being developed for several indications including opioid-induced 
constipation, gastroparesis, and ulcerative colitis.  
Whereas ST-producing bacteria utilize GC-C biology to manipulate host 
physiology and enhance transmission, mammals rely on guanylin- and uroguanylin-
induced GC-C activation to maintain intestinal homeostasis (Arshad & Visweswariah, 
2012). In addition to regulating fluid and ion secretion, GC-C-mediated cGMP increases 
have been shown to play a role in suppressing intestinal inflammation and colon cell 
proliferation.  
 
GC-C and CRC  
 It has been suggested that GC-C acts as a cell cycle regulator and that activation 
of the enzyme suppresses tumor formation in the intestines. The colonic epithelia of GC-
C-null mice has been found to be more susceptible to develop tumors in response to 
carcinogens or inherited germ line mutations compared to that of wildtype mice (Basu et 
al., 2014). Li et al. (2007) examined tumorigenesis in mice expressing GC-C and in GC-
C-knockout mice. Some mice in each group had mutations in the Apc (Apc
Min/+
) gene, 
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leading to rapid formation of polyps. In the Apc
Min/+
 mice that were also deficient in GC-
C, the researchers found increased tumor incidence in the colon compared to those 
expressing GC-C. Increased tumorigenesis was also observed in the small intestine of the 
GC-C knockout mice. These results were duplicated in non-Apc
Min/+
)  mice who were 
instead exposed to azoxymethane, a potent carcinogen.  The authors also noted that there 
was an increase in number, but not size, of tumors in the colons of GC-C knockout mice 
compared to those expressing GC-C, suggesting that GC-C may not affect proliferation in 
the mouse colon, but instead may impact tumor differentiation via DNA damage. 
Increased DNA damage, measured using γ-H2AX, was observed as well, supporting this 
hypothesis. The authors concluded that the tumorigenesis observed in the colons of 
Apc
Min+
 mice lacking GC-C was the result of corrupted genomic integrity, not 
hyperproliferation. Chromosomal instability or impaired DNA repair, for example, may 
be the primary drivers of carcinogenesis in the large intestine.  
 While Li et al. (2007) suggest that genomic changes, instead of disruption of cell 
cycle checkpoints, are responsible for tumorigenesis in the colon, the authors propose that 
the story is reversed in the small intestine. In the same GC-C deficient Apc
Min/+
  mice, 
tumor size, rather than number, compared to mice expressing GC-C appeared to be the 
driver of the increased tumor burden in this part of the gastrointestinal tract. Increased 
proliferation of enterocytes was also observed and was found to be associated with 
increased expression of β-catenin. Genomic abnormalities were not detected in the small 
intestine. Therefore, it appears that GC-C may suppress tumor development and growth 
via two distinct mechanisms that act in different parts of the gastrointestinal tract.  
17 
 
Additional evidence of a potential role of GC-C in colorectal cancer came from 
studies showing ectopic GC-C expression in metastatic colorectal tumors (Carrithers et 
al., 1996; later supported by Birbe et al., 2005; Schulz et al. 2006).  Soon after, the 
guanylate cyclase C agonists ST and uroguanylin were found to have strong, dose-
dependent cytostatic effects in two human colon carcinoma cell lines, T84 and Caco2, 
which express GC-C (Pitari, Di Guglielmo, Park, Schulz, & Waldman, 2001). 
Importantly, this inhibition of proliferation was not observed in SW480 cells, which do 
not express GC-C. The cytostatic effects were mimicked by a cell-permeant cGMP 
analog, and were potentiated by inhibiting the cGMP-specific phosphodiesterase inhibitor 
(PDE5). Furthermore, an inactive analog of ST failed to produce similar effects. These 
data strongly suggest that the observed cytostasis in T84 and Caco2 cells was mediated 
by GC-C catalyzed cGMP accumulation (Pitari, Di Guglielmo, Park, Schulz, & 
Waldman, 2001).  
 Wilson et al. (2014) recently assessed the expression of guanylin in CRC cells to 
see if a change in the expression of this GC-C agonist is associated with CRC. Guanylin 
mRNA and guanylin protein were found to be significantly reduced in CRC tumors when 
compared with normal epithelial specimens. Guanylin mRNA was reduced 100- to 1,000-
fold in nearly all of the tumors compared with adjacent epithelia. Guanylin, which was 
detected in all 30 normal specimens, was found in none of the 54 tumors examined. 
These data suggest that the loss of guanylin and the presumed decrease in GC-C 
expression and activity may disrupt intestinal homeostasis, potentially leading to 
tumorigenesis.  
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If diminished GC-C activity is at least partially responsible for tumorigenesis or 
proliferation, it follows that GC-C activation may suppress malignant activities, as was 
initially shown by Pitari et al. (2001). More recent studies have suggested potential 
mechanisms for such neoplastic inhibition. Lubbe et al. (2009) showed that GC-C-
mediated cGMP signaling leads to a redistribution of MMP-9, resulting in diminished 
capacity for the cytoskeleton reorganization that contributes to the metastasis of CRC and 
other cancer types (Powell, Bennett, Orange, Horgan, & Edwards, 2012; Chou et al., 
2012). These mechanistic findings were supported by reduced establishment of CRC 
metastases in mouse peritoneum in vivo. Lin et al. (2010) suggested that inhibition of 
Protein Kinase B, otherwise known as AKT, might be another potential mechanism for 
GC-C-induced tumor suppression. AKT has been suggested as an inducer of cell survival 
and metastasis (Agarwal, Brattain, & Chowdhury, 2013). Lin et al. also demonstrated that 
oral administration of cGMP to GC-C deficient mice reversed the accelerated epithelial 
proliferation that was observed before cGMP treatment. This evidence provides 
additional support to the hypothesis that the GC-C/cGMP pathway contributes to the 
suppression of intestinal tumorigenesis and carcinoma metastasis.  
 
Cyclooxygenases  
 Cyclooxygenases (COX) are integral membrane glycoprotein enzymes that 
catalyze two steps in the conversion of arachidonic acid (AA) to pro-inflammatory 
prostaglandins (Andersen & Vogel, 2014). COX is somewhat unique in that it has two 
catalytic activities. COX first exerts its bis-oxygenase activity and converts arachidonic 
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acid to PGG2. It then has a peroxidase activity, which results in the reduction of PGG2 to 
PGH2, which acts as the primary substrate for synthesis of specific prostaglandins 
(Minghetti, 2004).  
 
Adapted from (Zarghi & Arfaei, 2011). 
Figure 6. Summary of Prostanoid Synthesis. 
Cyclooxygenases catalyze two key reactions in biosynthesis of prostaglandins.  
The two primary cyclooxygenase isoforms, COX-1 and COX-2, are coded by 
separate genes found respectively on chromosome 9 and 1. While COX-1 is 
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constitutively expressed and generally performs housekeeping functions, COX-2 is not 
usually expressed in normal tissues, but its expression can be rapidly induced by various 
stimuli including growth factors, pro-inflammatory molecules, and other cytokines (Sade, 
Tuncay, Cimen, Severcan, & Banerjee, 2012; Minghetti, 2004). The expression of COX-
2 is regulated through a TATA box and several transcription factors with binding sites in 
the gene’s promoter region (Minghetti, 2004). COX-1, on the other hand, lacks a TATA 
box and is thought of as a typical housekeeping protein. Because the two isoforms have 
functional domains that are mostly conserved, some COX inhibitors inhibit both forms. 
Several of the classical NSAIDs function by inhibiting both COX enzymes. Inhibitors 
specific to one isoform or the other have been discovered. COX-2-specific inhibitors 
were originally developed in hopes of preserving the housekeeping activity of COX-1, 
while suppressing the pro-inflammatory activity caused by COX-2 expression and 
activity (Andersen & Vogel, 2014).  
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Adapted from (Zarghi & Arfaei, 2011). 
Figure 7. Roles of COX-1 and COX-2 and Differences between Classical NSAIDs 
and Selective COX-2 Inhibitors. 
Inhibitors specific for COX-2 theoretically would preserve homeostatic cyclooxygenase 
activity via COX-1 while suppressing inflammation, cell growth, and tumor formation.  
 
COX-2 expression has been associated with many disease states and has been 
shown to be induced by various mitogenic and inflammatory signals (Minghetti, 2004). 
In the gastrointestinal tract, COX-2 expression has been linked to the presence of certain 
bacteria, such as Lactobacillus rhamnosos, and may play a role in the immune response 
to environmental factors such as diet or the composition of the intestinal microbiome 
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(Korhonen, Kosonen, Korpela, & Moilanen, 2004). Inhibitors specific to the COX-2 
isoform were originally developed to achieve anti-inflammatory and analgesic effects 
without the gastrointestinal toxicity caused by non-specific NSAIDs (Wallace & 
Devchand, 2005). However, COX-2 may have important roles in maintaining 
gastrointestinal homeostasis in response to environmental challenges. For instance, some 
of the prostaglandins produced following COX-2 activity appear to have important roles 
in strengthening mucosal defense by stimulating mucus secretion and maintaining blood 
flow to the mucosa. COX-2 inhibitors have been shown to delay healing of gastric ulcers 
(Wallace & Devchand, 2005), possibly as a result of restricting blood flow and causing 
disruption to the mucosal barrier in the gut.  
While the mechanisms described above certainly play a role in the gastrointestinal 
toxicity observed following NSAID administration, they may also contribute to the role 
of COX-2 in CRC.  
 
COX-2 and CRC 
Constitutive COX-2 expression has been observed in many human tumors and 
appears to occur early on in the carcinogenic process, leading to tumor cell proliferation, 
angiogenesis, and eventual metastasis (Jendrossek, 2013).  An increase in COX-2 
expression has also been connected to poor prognosis in CRC patients (Lin, Lin, Lee, 
Liu, & Lee, 2013). In their study, Lin et al. examined COX-2 expression in human CRC 
tumors and adjacent normal mucosa. Most tumor specimens had very low levels of COX-
2 compared to the surrounding normal tissue. However, when tumors had high COX-2 
expression, the patients from which the specimens were derived had higher recurrence 
23 
 
rates and lower survival rates. As a result, COX-2-specific inhibitors have been explored 
as potential treatments for cancer.  
COX-2 inhibition has been shown to sensitize tumor cells to chemotherapy or 
radiotherapy, and appears to induce apoptosis as well, potentially by inhibiting AKT, 
Survivin, and other molecules responsible for cell division and survival (Jendrossek, 
2013).  The exact mechanisms underlying the rationale for COX-2 inhibition in cancer 
treatment remain unclear, as COX-independent anti-neoplastic and pro-apoptotic effects 
following NSAID administration have been observed (Sade, Tuncay, Cimen, Severcan, & 
Banerjee, 2012). This suggests that there may be promiscuous activities from either the 
drugs themselves or their metabolites that are partially responsible for their effects. 
Nevertheless, strong data from in vitro, in vivo, and clinical studies support the potential 
for NSAIDs, particularly the COX-2 inhibitor celecoxib (Celebrex), in preventing and 
treating CRC (Lee et al., 2012; Pyrko et al., 2006; Nan et al., 2015; Jendrossek, 2013; 
Andersen & Vogel, 2014).  
 
Celecoxib 
Celecoxib was the first COX-2 selective inhibitor to be approved by any drug 
regulatory agency (McCormack, 2011).  Other members of the COX-2 selective inhibitor 
class (i.e. –coxibs) include rofecoxib, valdecoxib, and etoricoxib (Zarghi & Arfaei, 
2011), although celecoxib is the only currently approved –coxib. Celecoxib and other 
members of this class have been associated with adverse cardiovascular events. 
Rofecoxib was found to be associated with increased risk of heart attack and stroke, and 
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was withdrawn from the market in 2004. Valdecoxib was withdrawn the following year 
as well.  
Celecoxib is currently approved by the United States Food and Drug 
Administration (FDA) for the treatment of several pain-related and inflammatory 
conditions, including osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing 
spondylitis (AS), acute pain, and primary dysmenorrhea (GD Searle, 2011). The drug was 
also once approved by the EMA for the reduction of the number of adenomatous 
intestinal polyps in patients with FAP, but this approval has since been withdrawn. 
Nevertheless, coxibs have continued to be reputed for preventing development of 
adenomatous polyps. In fact, a significant reason for the withdrawal of rofecoxib was that 
an increase in cardiovascular risks was observed during a study that was assessing the 
drug’s ability to prevent polyps (Zarghi & Arfaei, 2011). In one meta-analysis, celecoxib 
has not been found to significantly increase incidence of cardiovascular events over high 
doses of traditional NSAIDs (Kearney, Baigent, Godwin, Halls, Emberson, & Patrono, 
2006), although this result is not consistent across other studies (McCormack, 2011). 
Celecoxib has been found in large safety studies to have significantly lower incidence of 
gastrointestinal (GI) complications compared to non-selective NSAIDs (McCormack, 
2011). 
 Celecoxib was selected as the COX-2 inhibitor for use in the research presented 
in this thesis because of the decreased risk of GI toxicity and because celecoxib is the 
only COX-2 inhibitor approved by the FDA. 
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Adapted from (Zarghi & Arfaei, 2011). 
Figure 8. Chemical Structure of Celecoxib.  
 
Rationale for Celecoxib/ST Combination in Treating CRC  
 Based on evidence supporting the independent use of GC-C agonists and 
celecoxib to prevent growth of CRC cells and induce tumor reduction, a combination of 
these two approaches may be an effective treatment approach in the CRC setting. 
However, Booth et al. (2015) recently showed that inhibition of PDE5, the molecule 
responsible for most cGMP degradation, by sildenafil potentiated the ability of celecoxib 
to induce apoptosis in human glioma cells. It is currently unclear whether similar effects 
would be obtained in CRC cells. Nevertheless, this study suggests that co-administration 
of celecoxib and GC-C agonists may lead to synergistic apoptotic and antiproliferative 
effects, as GC-C-induced cGMP accumulation may potentiate celecoxib’s pro-apoptotic 
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activities in a manner similar to that observed following the inhibition of PDE5 by 
sildenafil. If a treatment with such effects could be translated to the clinic, it could 
provide physicians and patients with an important addition to the CRC therapeutic 
arsenal. However, the combination of celecoxib and a GC-C agonist may be best 
positioned in prophylactic regimens for patients with histories of adenomas or CRC or in 
patients with strong genetic predispositions for CRC, such as those with FAP, MAP, or 
HNPCC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
27 
 
 
Chapter II 
Materials and Methods 
 
Cell Proliferation by Thymidine Incorporation 
 All cells used during the course of this research were T84 cells (ATCC P/N CCL-
248), which are cultured from a human colorectal adenocarcinoma. T84 cells were 
cultured in DMEM/F-12 50/50 (Mediatech P/N 10-092-CV) supplemented with 1% L-
Glutamine (VWR P/N 45000-676) and 5% Fetal Bovine Serum (FBS; VWR P/N 45001-
106).  
 Cells were split at 20,000/well into four 96-well plates (Costar P/N 3610) using 
the medium described above and were incubated at 37°C for twenty-four hours. Cells 
were then starved of FBS to synchronize cell cycles by removing the complete media, 
washing the cells with 100μL of DMEM/F-12, and replacing the medium with 100μL of 
DMEM/F-12. Cells were starved for twenty-four hours.  
 After synchronization, the media were removed and replaced with 80μL of 
DMEM/F-12, 10μL of treatment (treatments described in Table 1), and 10μL of FBS 
(rows B-H) or 10 μL of DMEM/F-12 (row A). All treatments contained 0.5% dimethyl 
sulfoxide (DMSO) because DMSO is necessary for celecoxib solubility. Camptothecin 
(CPT; Tocris P/N 1100) was used as a positive anti-proliferation control. 1 μM ST 
(PolyPeptide Laboratories P/N 0603-156) was used both in combination with varying 
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doses of celecoxib and alone. Two plates were incubated at 37°C for eighteen hours and 
two more were incubated for forty-two hours. After incubation, 0.2μCi of [3H]-thymidine 
(American Radiolabeled Chemicals P/N ART 0178A) was added to each well. The plates 
were then incubated for an additional six hours to allow the radiolabeled thymidine to be 
incorporated into the cells’ DNA.  
 
Row Columns 1-3 
(celecoxib 
alone) 
Columns 4-6 
(CPT) 
Columns 7-9 (celecoxib + 
1 μM ST) 
Columns 10-12 
(ST alone) 
A Vehicle (no FBS) 
B Vehicle 
C 0.125 μM 0.00001 μM 0.125 μM + ST 0.00001 μM 
D 1.25 μM 0.0001 μM 1.25 μM + ST 0.0001 μM 
E 6.25 μM 0.001 μM 6.25 μM + ST 0.001 μM 
F 12.5 μM 0.01 μM 12.5 μM + ST 0.01 μM 
G 25 μM 0.1 μM 25 μM + ST 0.1 μM 
H 50 μM 1 μM 50 μM + ST 1 μM 
 
Table 1. Treatments in Cell Proliferation Assay (Thymidine Incorporation).  
 After incubation, the medium was removed and 50μL of trypsin was added to 
each well. Once the cells were visibly detached from the plates, they were transferred 
onto a filter plate (Millipore FB P/N MADVNOB) that had been pre-washed with 150 μL 
of water and connected to an aspirator. Each filter plate was washed with 150 μL of water 
6 times. When all liquid was aspirated after the last wash, each filter was removed and 
allowed to dry for 60 minutes in a 50ºC oven. After drying, filters were attached to 96 
well plates for counting. 80 μL of microscint (UltraGold MV, PerkinElmer P/N 6013159) 
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was added to each well and the amount of radioactivity was counted using a MicroBeta 
liquid scintillation counter. 
 
COX-2 Activity Assay 
The COX-2 activity assay was conducted using the COX Activity Assay Kit 
(Cayman Chemical P/N 760151). T84 cells were cultured in DMEM/F-12 50/50 
supplemented with 1% L-Glutamine and 5% FBS and were split into two 24-well plates. 
Because 0.5% DMSO was used in the proliferation assay, the same concentration was 
used in the enzyme activity assays in each well. Cells were treated with vehicle (0.5% 
DMSO), 1μM ST, or the combination of 50μM celecoxib and 1μM ST. Cells were 
subsequently incubated at 37° for 24 hours.   
Following treatment, cells were scraped from the plates using a rubber policeman 
and were harvested into 500 μL Eppendorf tubes. The tubes were centrifuged at 4°C for 
10 minutes at 1,000xG. The supernatant was extracted and pellets were sonicated in a 
buffer of 0.1M Tris-HCl pH 7.8 with 1mM EDTA. The cell fragments and buffer were 
then centrifuged at 4°C for 15 minutes at 10,000 x g. Supernatant was extracted and 
stored at -80°C. 
After samples were thawed, 150 μL of each sample was transferred to a 500 μL 
microfuge tube. The tubes were centrifuged at 8,000 x g for one minute. For the COX 
standard wells (n=4; “Std” in Figure 14), 150 μL assay buffer (100 mM Tris-HCl, pH 
8.0), 10 μL Heme, and 10 μL of the provided standard was added to a 96-well plate.  The 
background wells (n=4) were prepared using 120 μL assay buffer, 10 μL Heme, and 40 
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μL distilled water. Sample wells taken from each of the treatment groups (vehicle, ST 
alone, ST/celecoxib combination; n=16 each) were prepared using 120 μL assay buffer, 
10 μL Heme, and 40 μL of sample from the centrifuged microfuge tubes. The plate was 
then shaken gently for a few seconds and was incubated for 5 minutes at room 
temperature.  
After 5 minutes, 20 μL Colorimetric Substrate was added to each well. The 
reactions were then initiated by adding 20 μL arachidonic acid solution to each well. The 
plate was again shaken briefly and allowed to incubate for 5 minutes at room 
temperature. Following incubation, absorbance at 590 nm was read using a plate reader.  
Average absorbance was calculated for each treatment group and the average 
background value was subtracted from each treatment average. These corrected values 
are the corrected absorbances (ΔA590). The corrected absorbances were subsequently 
inserted into the following formula to calculate total COX activity.  
 
Adapted from COX Activity Assay Kit.  
Figure 9. Equation for Calculating Total COX Activity. 
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cGMP Accumulation Assay 
 GC-C activity, measured by accumulation of cGMP, was assessed using a 
modification of the method described by Busby et al. (2010). T84 cells were cultured in a 
24-well plate in DMEM/F12 supplemented with 2.5 mM glutamine and 5% FBS. Total 
medium per well was 1mL. 30 minutes before treatment, the medium was removed and 
replaced with a medium containing 1 mM isobutylmethylxantine (IBMX). Plates were 
incubated for 30 minutes at 37°C. The medium was then removed and vehicle wells 
(n=8) were filled with 1 mL DMEM/F12 supplemented with 2.5 mM glutamine, 5% 
FBS, and 1 mM IBMX. Wells assigned to the ST treatment group were filled with 1 mL 
DMEM/F12 supplemented with 2.5 mM glutamine, 5% FBS, 1 mM IBMX, and 1 μM ST 
(n=8). Wells assigned to the combination treatment group were filled with the same 
medium as the other groups as well as 50 μM celecoxib. The plate was then incubated for 
30 minutes in a 37ºC/5% CO2 incubator. After the 30 minutes of exposure, the media 
from the wells were aspirated and the cells were lysed in 1 mL of cold 0.1 M HCl and 
underwent one cycle of freezing at -80ºC and thawing. Cell lysates were then transferred 
to 1.5 mL microfuge tubes and were cleared of cell debris by centrifugation at 15,000 X g 
at 4ºC. Protein concentration in the lysates was measured by the method of Bradford 
(1976). 
 The concentration of cGMP in the T84 cell lysates was measured using a cGMP 
enzyme immunoassay kit (GE Healthcare Amersham cGMP Enzymeimmunoassay 
Biotrack System). 20 μL cell lysate from the vehicle treated cells was added to 4.5 μL 
1M Tris-HCl pH 8 and 175.5 μL assay buffer (50 mM sodium acetate pH 6 containing 
0.002% BSA and 0.01% preservative). 2 μL cell lysate from ST and ST/celecoxib treated 
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cells was added to 1.25 μL 1M Tris-HCl pH 8 and 196.75 μL assay buffer. cGMP in 
standards (2-512 fmol, prepared fresh in 200 μL assay buffer) and diluted cell lysates 
were acetylated with 20 μL acetylation reagent (1 part acetic anhydride, 2 parts 
triethanolamine). A zero standard was also included that did not contain any cGMP. 
Next, 50 μL of acetylated standards and samples were added to each well of a 96-well 
microplate, coated with donkey anti-rabbit IgG, containing 100 μL of diluted anti-cGMP 
serum. Two wells contained only 150 μL assay buffer and served as non-specific binding 
controls. After the plate was incubated for two hours at 4ºC, 100 μL of diluted cGMP 
conjugated with horse radish peroxidase (HRP) was added to each well and the plate was 
incubated for another hour at 4ºC. The contents from all wells were aspirated and each 
well was washed 4 times with 250 μL wash buffer (0.01 M phosphate buffer pH 7.5 
containing 0.05% Tween 20). After the last wash was removed and the plate blotted, 200 
μL HRP substrate (3,3’,5’5’-tetramethylbenzidine/hydrogen peroxide) was added and the 
blue color was allowed to develop for 20 minutes at room temperature. Color 
development was stopped by the addition of 100 μL of 1 M sulphuric acid. The optical 
density was read at 450 nm. For each sample, net optical density was determined by 
subtracting the optical density of the non-specific binding wells from the raw optical 
density of each sample. The %B/B0 was calculated by dividing the net optical density of 
each sample by the net optical density of the zero standard (B0) x 100. A standard curve 
(Figure 10) was generated by plotting the %B/B0 as a function of log cGMP 
concentration. cGMP in the cell lysates was calculated using the standard curve.  
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Adapted from GE Healthcare Amersham cGMP Enzymeimmunoassay Biotrack System.  
Figure 10. Example of cGMP Standard Curve. 
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Western Blot Experiments 
 After treatment (same treatments as used in COX and GC-C activity assays), the 
medium was aspirated and cells were washed in PBS once. Cells were subsequently lysed 
in PBS-0.2% Triton X-100 supplemented with protease and phosphatase inhibitors. 
Protein concentration in the lysates was assessed using the method described by Bradford 
(1976), using gamma globulin as the standard. 
 SDS-polyacrylamide gel electrophoresis and immunoblots were conducted using 
a modification of the method described by Kessler et al. (1995). Purified human COX-2 
(1mg, Sigma P/N C0858) and cell lysate proteins (4μg, 12μg, 40μg, and 104μg) were 
mixed with gel loading buffer, and were heated for 10 minutes at 70°C. Proteins were 
then separated in SDS-4-12% (NUPAGE Precast Mini Bis-Tris) using a constant voltage 
of 200V at room temperature for 40 minutes. After separation, the gels were soaked in 
transfer buffer (25mM Tris/192 mM glycine and 20% methanol) for 5 minutes, and 
proteins were transferred to polyvinylidene difluoride (PVDF) according to the method 
described by Towbin et al. (1979). Transfers were run overnight using a constant current 
of 10mA.  
 After the proteins were transferred, the membranes were soaked in water for 5 
minutes and Super Block PBS buffer (Thermo Fisher P/N 37515) containing 0.05% 
Tween-20 was applied for one hour at room temperature to block nonspecific protein 
binding sites on the membranes. Blotted proteins were treated overnight at 4°C with 
diluted anti-COX-2 antibody (Cell Signaling P/N 4842, diluted 1:1,000) or with diluted 
anti-Caspase-3 antibody (Santa Cruz Biotechnology P/N sc-7148 , diluted 1:5000) After 
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being washed 4 times in wash buffer (10mM Tris-HCL, ph 8, 150mM NaCl, 0.05% 
Tween 20) for 5 minutes per wash, the blots were treated with horse-radish peroxidase 
(HRP)-conjugated anti-rabbit IgG secondary antibody for 1 hour at room temperature. 
The blots were again washed 4 times in wash buffer. Immunoreactive peptides were 
visualized by reaction of the blots with the HRP chemiluminescent substrate system (Cell 
Signaling Technology, SignalFire™ ECL Reagent) and detection in X-ray film.  
   
36 
 
 
Chapter III 
Results 
 
Results of Thymidine Incorporation Assays 
The positive control CPT (DNA topoisomerase inhibitor) dose-dependently 
inhibited thymidine incorporation (cell division) in T84 cells, validating the anti-
proliferation assay. Celecoxib was found to dose-dependently inhibit thymidine 
incorporation/cell proliferation. The combination of ST and celecoxib, however, failed to 
further reduce thymidine incorporation in comparison to celecoxib alone. ST alone did 
not affect thymidine incorporation at any dose. These results were consistent between the 
24 and 48 hour time points at which tritium radiation was measured (Figure 11 and 
Figure 12).  
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Figure 11. Thymidine Incorporation Results from 2 Separate 96-well Plates over 24 
Hours. 
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Figure 12. Thymidine Incorporation Results from 2 Separate 96-well Plates over 48 
Hours. 
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Results of cGMP Accumulation Assay 
 
 The activity of GC-C, measured by accumulation of intracellular cGMP, was 
found to be significantly increased in cells treated with ST and in cells treated with the 
combination of ST and celecoxib in comparison to cells treated with vehicle alone 
(Figure 13). In cells treated with both ST and celecoxib, there was an apparent reduction 
in cGMP accumulation compared to cells treated with only ST. However, this difference 
was not statistically significant, which suggests that celecoxib does not interfere with 
GC-C activity or with ST’s ability to agonize such activity.  
 
***P < 0.001, ****P < 0.0001 (compared to vehicle) 
Figure 13. Levels of Intracellular cGMP in T84 Cells Measured after Treatment.  
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Results of COX Activity Assay  
 There was no difference in COX activity across the treatment groups (Figure 14). 
While the assay measured total COX activity and not COX-2 activity specifically, it is 
presumed that any change in COX activity in this experiment would be the result of 
changes to the COX-2 isoform due to the well-recognized specificity of celecoxib for 
COX-2 and not COX-1.  
 The results from this experiment provide further support for the hypothesis that 
COX-2 is not expressed in T84 cells and that the anti-proliferative activity of celecoxib 
occurs through a mechanism independent of COX-2.  
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Figure 14. COX Activity Measured in T84 Cells after Treatment.   
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Results of COX-2 Western Blot Experiment 
A western blot analysis using T84 cell lysates was used to confirm that COX-2 
protein is not detectable in these cells (Figure 15). Recombinant human COX-2 was used 
as a positive control for the blot. In addition to not being detected in the untreated T84 
cells, COX-2 was not detected in any of the treatment groups. There appears to have been 
cross-reaction between the COX-2 antibody and another protein (35 kDa) in the T84 
lysates. This cross-reaction may be an anomaly, or, as described in the discussion section, 
below, may be an interesting lead into identifying the COX-2-independent anti-
proliferative mechanism of celecoxib.  
 
 
 
 
 
Figure 15. Results of Western Blot Experiment for COX-2 in T84 Cells. 
 
 
 
COX-2 
Purified 
COX-2 
1μL 3μL 10μL 
T84 Cell 
Lysates 
~72 kDa 
43 
 
 
 
 
                                                
Figure 16. Unknown Protein Found to Cross-react with Anti-COX-2 Antibody. 
 
Results of Caspase-3 Western Blot Experiment 
 Caspase-3 was not detected in any of the treatment groups. Interestingly, this 
marker of cell death was not detected in LPS-treated T84 lysates either, which is 
surprising because LPS is expected to cause cell death, and therefore lead to detectable 
Caspase-3 levels.  
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Chapter IV 
Discussion 
 
 The results of these experiments do not support the hypothesis that GC-C agonism 
and COX-2 inhibition synergistically reduce tumor cell proliferation. Celecoxib was 
found to reduce proliferation of T84 cells in a dose-dependent manner. The potency of 
this reduction in proliferation was several orders of magnitude lower than that of the 
positive control, camptothecin. ST, the potent GC-C agonist used in this research, did not 
significantly reduce proliferation when used as a monotherapy, and did not potentiate the 
effects of celecoxib when the two drugs were used in combination.  
 The thymidine incorporation assay results appear to contradict the work 
previously published by Pitari et al. (2001). Unpublished research by the laboratory in 
which this thesis was conducted has also been unable to find an anti-proliferative effect 
of GC-C agonists in T84 cells. While ST did not significantly potentiate celecoxib’s anti-
proliferative effects in this study, this result may be attributed to celecoxib’s 
comparatively potent activity, which may have made it difficult to detect whether there 
was a subtle reduction in proliferation after ST administration. In fact, according to 
Figures 11 and 12, it appears that there may actually be a slight reduction in proliferation 
even though the difference was not statistically significant. 
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 Although celecoxib was able to prevent proliferation, this effect appears to be 
independent of the COX-2 enzyme, as COX-2 protein was not found in T84 cells. This is 
consistent with previous research demonstrating that COX-2 is not expressed under 
normal physiological conditions (Korhonen, Kosonen, Korpela, & Moilanen, 2004) and 
with other work showing that celecoxib’s antiproliferative effect is independent of COX-
2 in other types of cancer as well as in CRC (Sade et al., 2011; Gaullouet et al., 2014). 
Furthermore, a reduction in arachidonic acid was not observed in treated cells. This 
supports the finding that COX-2 is not expressed in these cells, as celecoxib is known to 
be a potent inhibitor of COX-2 and not of COX-1.  
The presence of Caspase-3 was used to assess whether any of the treatments had a 
cytotoxic effect. The highest dose of celecoxib was used in the Western blot experiment 
because it was assumed that any effects on enzyme activity would be best observed using 
the highest dose. It has previously been demonstrated that Caspase-3 is activated and 
detectable in T84 cells following incubation with Clostridium difficile Toxin A (Carneiro 
et al., 2006). In their experiment, Caspase-3 was not detected by Western analysis until 
18 hours of incubation, and levels appeared to peak at 48 hours. As expected, ST 
activation of GC-C had no cytotoxic effects, as measured by Caspase-3 induction. ST did 
not induce apoptosis when combined with celecoxib. LPS was unable to produce 
detectable Caspase-3 even after 24 hours of incubation. It is possible that either an 
increase in the concentration of LPS or the incubation time may be required to cause a 
detectable increase in the apoptotic protein.  
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 At first glance, these results appear to conflict somewhat with the data generated 
by Booth et al. (2015) in which the researchers found that celecoxib had cytotoxic effects 
and that these effects were potentiated by inhibiting the PDE5, which results in an 
accumulation of cGMP.  In the research presented in this thesis, a high dose of celecoxib 
was not found to be cytotoxic as shown by a lack of detectable protein in a caspase-3 
western analysis. This result is inconsistent with previous additional previous work from 
Gallouet et al. (2014), suggesting perhaps that the occurrence of cytotoxic activity of 
celecoxib may be variable based on cell type.  
 The inability of GC-C agonism to reduce proliferation was not entirely 
unexpected after reading the work of Li et al. (2007). In this paper, the authors suggest 
that inhibiting hyperproliferation was the primary mechanism by which GC-C prevents 
tumor development and growth in the small intestine. In the large intestine, however, the 
authors found that reduction in tumor burden was instead associated with reduced 
genomic abnormalities. Cell proliferation in the large intestine appeared to be unaffected. 
As a result, the failure of ST to reduce proliferation in T84 cells, which are, of course, 
cancerous cells derived from the colon and not the small intestine, is not inconsistent with 
previous work conducted in vivo.  
 
Limitations 
 One of the primary limitations of these experiments is that they were all 
conducted in T84 cells. While this is a commonly used cell line in research of 
gastrointestinal function and disorders, it is, of course, derived from a single 
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adenocarcinoma from a single patient. It could therefore differ significantly in terms of 
DNA and protein expression and other factors from other human CRC-derived cell lines 
and ultimately from the CRC found in most patients. More robust results could be 
obtained by conducting the same experiments in multiple cell lines, such as in HCT 116 
cells.  
 While a terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) 
assay would have been the preferred method of assessing whether celecoxib and the 
combination of ST and celecoxib induced apoptosis, this was not practical during the 
course of the research described here for lab-specific reasons. The Caspase-3 Western 
protocol had been used successfully in the lab in which this research was conducted and 
was deemed to be a suitable replacement to assess whether the treatments were cytotoxic. 
Interestingly and unexpectedly, Caspase-3 was not detected in LPS-treated T84 cells as 
described above. With more time and resources, it would be worthwhile to find another 
method to assess cytotoxicity. For instance, in the research conducted by Carneiro et al. 
(2006), Caspase-8 and Caspase-9 were detected prior to Caspase-3. Perhaps these 
proteins may be more easily detected in T84 cells following treatment with LPS or 
ST/celecoxib.  
 
Future Directions 
 As described above, the role of GC-C in preventing tumor growth and 
development may be different in the colon versus the small intestine. It would be 
interesting to perform a similar experiment assessing changes in genomic integrity, rather 
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than proliferation, to evaluate whether activation of GC-C may actually prevent 
carcinogenesis at a genomic level.  For example, looking at markers of DNA repair or 
chromosomal stability may provide additional insight into the mechanism by which GC-
C controls CRC development, if, in fact, it does. In addition, it may be worthwhile to test 
whether a GC-C agonist can reduce proliferation in adenocarcinomas derived from the 
small intestine.  
An obvious progression from this research would be to assess whether celecoxib-
like compounds with no activity on COX-2 have the same effect on proliferation. If the 
anti-proliferative effects were found to be the same, this would provide additional 
confirmation that celecoxib inhibits cell proliferation through a pathway independent of 
COX-2.  
One of the more interesting results from this research was the finding of a cross-
reactant protein (at ~35 kDa) to the anti-COX-2 antibody used in the Western 
experiment. While this finding could easily be anomalous, resulting simply from random 
cross-reactivity, it could also be an intriguing starting point for further research into the 
mechanism by which celecoxib exerts its anti-proliferative effects. If the anti-COX-2 
antibody is able to bind to this mystery protein, it follows that the protein may share a 
binding region with COX-2, which could be the location at which celecoxib acts in both 
proteins.  
It may be worthwhile to investigate the identity of this unknown protein and 
assess whether celecoxib actually binds directly to it. If celecoxib is found to bind to the 
unknown protein, a suitable next step might be to evaluate the function of this protein to 
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see if it is involved in any way in the control of the cell cycle or in any apoptotic 
pathways. If this is found to be the case, it may explain celecoxib’s COX-2-independent 
effects.  
 
Other Combinations with GC-C Agonists 
 Although agonism of the GC-C pathway with ST did not inhibit cell proliferation 
in this study either alone or in combination with celecoxib, it is possible that additional 
drug combinations may result in enhanced activity against CRC.  
 Activation of the tyrosine kinase c-src has been strongly associated with CRC and 
appears to be an indicator of poor prognosis in patients with increased expression and 
activity (Basu, Bhandari, Natarajan, & Visweswariah, 2009). Interestingly, GC-C has 
been identified as a substrate of c-src phosphorylation (Basu et al., 2009; Singh, 2003). 
This phosphorylation has an inhibitory effect on GC-C, leading to a reduction in cGMP 
following binding of guanylin, uroguanylin, ST, or another GC-C agonist when compared 
to the un-phosphorylated enzyme. Inhibition of c-src using dasatinib, which is approved 
for treatment of several cancers and has been shown to be efficacious in killing human 
CRC cells (Kopetz et al., 2009), may therefore potentiate the activity of a GC-C agonist 
in an environment in which c-src is active. This may simply lead to an increase in the 
effects typically seen upon GC-C agonism (increased motility and decreased pain). 
However, if GC-C is in fact partly responsible for cell cycle regulation (though this effect 
was not seen in the research presented in this thesis), the potentiation of its activity may 
result in decreased tumor growth.  
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Basu et al. (2009) further demonstrate that phosphorylation of GC-C leads to 
additional activation of c-src. It follows that activation of GC-C above levels typically 
induced in the gut by the endogenous hormones guanylin and uroguanylin may lead to 
decreased c-src activation, although this depends entirely on whether decreased cGMP or 
simply the presence of the additional phosphate group on GC-C is responsible for the 
enhanced c-src activation.  
 
Other Combinations with COX-2 Inhibitors 
 Although the effects on proliferation seen after celecoxib administration appear to 
be independent of COX-2, the prostanoid biosynthesis pathway mediated by the 
cyclooxygenases may be an interesting target for other drug combinations with potential 
synergistic effects. Such combinations may be ideally suited for inflammatory conditions, 
rather than cancer. 
 One combination that may be worth investigating in gastrointestinal inflammatory 
disorders could include a COX-2 inhibitor and a fatty acid amide hydrolase (FAAH) 
inhibitor. The FAAH enzyme mediates the hydrolysis of anandamide (AEA) and other 
endogenous fatty acid amides that act as cannabinoids (i.e. they act on cannabinoid 
receptors) (Romero, Hillard, Calero, & Rabano, 2002). Because anandamide hydrolysis 
produces arachidonic acid, the primary substrate for cyclooxygenases, dual FAAH and 
COX-2 inhibition may lead to synergistic anti-inflammatory effects. One important 
outcome of this potential synergism is that co-administration of a FAAH inhibitor may 
allow for a reduction in the dose of a COX-2 inhibitor. As described earlier in this paper, 
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even though COX-2 inhibitors are effective NSAIDs, they are also associated with 
serious cardiovascular concerns. As a result, if a combination product could produce the 
same anti-inflammatory effects without needing high doses of the COX-2 inhibitor, it 
may serve as a helpful addition to physicians’ treatment arsenal. Of course, the safety and 
tolerability of each drug involved in the combination and the combination itself would 
need to be rigorously assessed in addition to efficacy. 
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Appendix 
Definition of Terms 
 
“Adenoma”: A benign tumor formed from glandular structures in epithelial tissue 
“Agonist”: A substance that binds to and activates a receptor to stimulate activity by the 
receptor 
“Apoptosis”: The process of programmed cell death that occurs in multicellular 
organisms 
“Benign”: Lacking the ability to invade neighboring tissue or metastasize; Not cancerous  
"cAMP": Cyclic Adenosine Monophosphate. A second messenger derived from 
adenosine triphosphate (ATP) and used for intracellular signal transduction.  
“Carcinoma”/“adenocarcinoma”: A malignant tumor derived from epithelial cells 
"cGMP": Cyclic Guanosine Monophosphate. A second messenger derived from 
guanosine triphosphate (GTP) and used for intracellular signal transduction 
“COX”: Cyclooxygenase. An enzyme that catalyzes the formation of pro-inflammatory 
compounds called prostaglandins from arachidonic acid.  
“Endogenous”: Originating from within an organism 
“Epigenetic”: Relating to or arising from nongenetic influences on gene expression 
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“Epithelial tissue”: One of the four basic types of animal tissue. Epithelial tissue lines 
cavities and surfaces of blood vessels and organs throughout the body. 
"GC-C": Guanylate Cyclase C. An enzyme found in the luminal intestinal epithelial that 
catalyzes the formation of cGMP. 
"Guanylin": A peptide secreted by colonic goblet cells that acts as an agonist of GC-C.  
“Inhibitor”: A substance that binds to an enzyme and decreases its activity.  
“Lumen”: The inside space of a tubular structure (e.g. intestine). 
“Malignant”: Tending to invade normal tissue or to recur after removal; Cancerous.  
“Metastasis”: The spread of cancer from one organ or part to another not directly 
connected organ or part.  
“Neoplasia”: Abnormal growth of tissue. 
“Paracrine”: A form of cell to cell communication in which a cell produces a signal to 
induce changes in nearby cells.  
“Pathogenesis”: The manner of development of a disease. 
“Polyp”: Abnormal growth of tissue projecting from a mucous membrane.  
“Proliferation”: Rapid reproduction of cells. 
"Uroguanylin": A peptide secreted by enterochromaffin cells that acts as an agonist of 
GC-C.  
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“Second messenger”: A molecule that relays signals received at receptors on the cell 
surface to target other molecules in the cell.  
"ST": Heat-Stable Enterotoxin. Bacterial derived secretory peptides that act as potent 
agonists of GC-C.  
“Synergism”: Interaction of discrete agents such that the total effect is greater than the 
sum of individual effects. 
 
